Expert Interview
Navigating New Frontiers in Follicular Lymphoma: An In-depth Look at Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel)
Ticker(s): BMYInstitution: Mayo Clinic
- Professor of Medicine in the Division of Hematology/Oncology at the Mayo Clinic Florida
- Manages 50 patients with Waldenström's macroglobulinemia and can speak to the data available for iopofosine and the CLOVER-WaM study.
- Clinical focus includes the treatment of plasma cell disorders, multiple myeloma (MM), Waldenström's macroglobulinemia, and chronic lymphocytic leukemia (CLL).
Could you describe how Breyanzi's mechanism of action, targeting CD19 with a 4-1BB costimulatory domain, is potentially transformative for patients with relapsed or refractory follicular lymphoma?
Added By: slingshot_insightsIn the TRANSCEND FL study, Breyanzi achieved high rates of complete response in patients. What does this signify for the treatment landscape of follicular lymphoma, especially considering these were high-risk, second-line patients?
Added By: slingshot_insightsHow does the efficacy and safety profile of Breyanzi compare with traditional therapies or other CAR T cell therapies currently in use for follicular lymphoma?
Added By: slingshot_insightsWith the upcoming PDUFA decision on May 23 for Breyanzi in FL, what are the potential implications for patient care should this therapy receive approval?
Added By: slingshot_insightsBreyanzi's trials reported manageable safety profiles but noted occurrences of cytokine release syndrome and neurotoxicity. How should healthcare providers prepare to manage these side effects effectively?
Added By: slingshot_insightsHow would oncologists determine the best candidates for Breyanzi treatment, and what are the challenges in ensuring broader access to this therapy for eligible patients?
Added By: slingshot_insightsHow do you sequence BsAb and CAR-T for FL patients?
Added By: wzhu0611Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
